• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

呼吸道合胞病毒:当前的治疗策略和疫苗方法。

Respiratory syntycial virus: Current treatment strategies and vaccine approaches.

机构信息

Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, USA.

Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, USA.

出版信息

Antivir Chem Chemother. 2020 Jan-Dec;28:2040206620947303. doi: 10.1177/2040206620947303.

DOI:10.1177/2040206620947303
PMID:32741202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7412623/
Abstract

Respiratory Syncytial Virus is a yearly respiratory virus that causes significant frequencies of morbidities, particularly in the young and elderly populations. However, preventive vaccines and/or treatment therapies are generally lacking, although much attention is now being placed on this virus. Moreover, there are now multiple strategies currently being explored in a race to the first licensed vaccine. While vaccines are being developed, multiple treatment strategies are being explored to attenuate the severity of infection and thus reduce hospitalization rates in vulnerable populations. This review outlines current strategies to prevent or treat this virus in the hopes of reducing significant human morbidity and mortality that occurs yearly with this seasonal virus.

摘要

呼吸道合胞病毒(RSV)是一种常见的呼吸道病毒,每年都会导致大量发病率,尤其是在儿童和老年人中。然而,目前一般缺乏预防疫苗和/或治疗方法,尽管现在人们对这种病毒给予了高度关注。此外,目前正在探索多种策略,以期率先开发出许可疫苗。在开发疫苗的同时,还在探索多种治疗策略,以减轻感染的严重程度,从而降低弱势人群的住院率。本综述概述了预防或治疗这种病毒的现有策略,以期减少每年这种季节性病毒导致的大量人类发病率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27cb/7412623/4d991058c869/10.1177_2040206620947303-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27cb/7412623/4d991058c869/10.1177_2040206620947303-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27cb/7412623/4d991058c869/10.1177_2040206620947303-fig1.jpg

相似文献

1
Respiratory syntycial virus: Current treatment strategies and vaccine approaches.呼吸道合胞病毒:当前的治疗策略和疫苗方法。
Antivir Chem Chemother. 2020 Jan-Dec;28:2040206620947303. doi: 10.1177/2040206620947303.
2
Advances in and the potential of vaccines for respiratory syncytial virus.呼吸道合胞病毒疫苗的进展和潜力。
Expert Rev Respir Med. 2013 Aug;7(4):411-27. doi: 10.1586/17476348.2013.814409.
3
Respiratory syncytial virus: reverse genetics and vaccine strategies.呼吸道合胞病毒:反向遗传学与疫苗策略
Virology. 2002 May 10;296(2):204-11. doi: 10.1006/viro.2002.1437.
4
A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.一种表达呼吸道合胞病毒(RSV)F或G蛋白的单剂量重组副流感病毒5载体疫苗可保护棉鼠和非洲绿猴免受RSV攻击。
J Virol. 2017 May 12;91(11). doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.
5
Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.疫苗和相关生物制品咨询委员会会议摘要,会议旨在评估预防 RSV -naive 婴儿呼吸道合胞病毒病的候选疫苗。
Vaccine. 2020 Jan 10;38(2):101-106. doi: 10.1016/j.vaccine.2019.10.048. Epub 2019 Nov 6.
6
Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.呼吸道合胞病毒疫苗:近期在研疫苗的最新情况
Future Microbiol. 2016 Oct;11:1479-1490. doi: 10.2217/fmb-2016-0106. Epub 2016 Oct 18.
7
A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.一种安全有效的 BCG 载体疫苗,用于预防由人类呼吸道合胞病毒引起的疾病。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2092-2097. doi: 10.1080/21645515.2017.1334026. Epub 2017 Jun 9.
8
Vaccines against human respiratory syncytial virus in clinical trials, where are we now?在临床试验中,针对人类呼吸道合胞病毒的疫苗,我们现在进展如何?
Expert Rev Vaccines. 2019 Oct;18(10):1053-1067. doi: 10.1080/14760584.2019.1675520. Epub 2019 Oct 14.
9
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.单剂量低剂量的cGMP重组卡介苗可引发针对人类呼吸道合胞病毒感染的保护性T细胞免疫,并预防小鼠的肺部病变。
Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Epub 2017 Jan 5.
10
Subunit and virus-like particle vaccine approaches for respiratory syncytial virus.呼吸道合胞病毒的亚单位和病毒样颗粒疫苗方法。
Curr Top Microbiol Immunol. 2013;372:285-306. doi: 10.1007/978-3-642-38919-1_14.

引用本文的文献

1
Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies.应对高于预期的呼吸道合胞病毒(RSV)导致的婴儿死亡率:改进治疗和报告策略。
Infect Drug Resist. 2023 Jan 27;16:595-605. doi: 10.2147/IDR.S373584. eCollection 2023.
2
Investigation of the Fuzzy Complex between RSV Nucleoprotein and Phosphoprotein to Optimize an Inhibition Assay by Fluorescence Polarization.荧光偏振优化 RSV 核蛋白与磷蛋白模糊复合物抑制分析的研究
Int J Mol Sci. 2022 Dec 29;24(1):569. doi: 10.3390/ijms24010569.
3
Impact of Respiratory Syncytial Virus and Influenza Virus Infection in the Adult Population in Spain between 2012 and 2020.

本文引用的文献

1
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.表达呼吸道合胞病毒F蛋白变体的基于修饰mRNA/脂质纳米颗粒的疫苗在呼吸道合胞病毒感染的啮齿动物模型中具有免疫原性和保护性。
NPJ Vaccines. 2020 Feb 14;5(1):16. doi: 10.1038/s41541-020-0163-z. eCollection 2020.
2
Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children.呼吸道合胞病毒疫苗 RSV/ΔNS2/Δ1313/I1314L 在呼吸道合胞病毒血清阴性儿童中的安全性和免疫原性。
J Infect Dis. 2020 Jun 16;222(1):82-91. doi: 10.1093/infdis/jiz408.
3
2012 年至 2020 年期间西班牙成人人群中呼吸道合胞病毒和流感病毒感染的影响。
Int J Environ Res Public Health. 2022 Nov 9;19(22):14680. doi: 10.3390/ijerph192214680.
4
Estimating the burden of adult hospitalized RSV infection using local and state data - methodology.利用本地和州数据估算成人住院 RSV 感染负担——方法学。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1958610. doi: 10.1080/21645515.2021.1958610.
5
Non-human primate models of human respiratory infections.人类呼吸道感染的非人灵长类动物模型。
Mol Immunol. 2021 Jul;135:147-164. doi: 10.1016/j.molimm.2021.04.010. Epub 2021 Apr 23.
Neonatal priming and infancy boosting with a novel respiratory syncytial virus vaccine induces protective immune responses without concomitant respiratory disease upon RSV challenge.
用一种新型呼吸道合胞病毒疫苗进行新生儿启动免疫和婴儿期加强免疫,在呼吸道合胞病毒攻击时可诱导保护性免疫反应,且不会伴随呼吸道疾病。
Hum Vaccin Immunother. 2020 Mar 3;16(3):664-672. doi: 10.1080/21645515.2019.1671134. Epub 2019 Oct 30.
4
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.基于表达呼吸道合胞病毒融合、核衣壳和抗终止病毒蛋白的黑猩猩腺病毒-155 病毒载体的在研呼吸道合胞病毒(RSV)疫苗的健康成年人中的首次人体随机研究,评估其安全性和免疫原性。
Clin Infect Dis. 2020 May 6;70(10):2073-2081. doi: 10.1093/cid/ciz653.
5
Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform.呼吸道合胞病毒融合蛋白编码DNA疫苗在预防炎症性疾病方面的效果不如病毒样颗粒平台。
Immune Netw. 2019 May 27;19(3):e18. doi: 10.4110/in.2019.19.e18. eCollection 2019 Jun.
6
The long road to protect infants against severe RSV lower respiratory tract illness.保护婴儿免受严重呼吸道合胞病毒下呼吸道疾病侵害的漫长道路。
F1000Res. 2019 May 2;8. doi: 10.12688/f1000research.18749.1. eCollection 2019.
7
Influence of Immunological Maturity on Respiratory Syncytial Virus-Induced Morbidity in Young Children.免疫成熟对幼儿呼吸道合胞病毒所致疾病的影响。
Viral Immunol. 2019 Mar;32(2):76-83. doi: 10.1089/vim.2018.0121. Epub 2018 Nov 30.
8
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.呼吸道合胞病毒疫苗领域:从墓地中吸取的教训和有前途的候选者。
Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18.
9
Naked DNA immunization with full-length attachment gene of human respiratory syncytial virus induces safe and protective immune response.用人呼吸道合胞病毒全长附着基因进行裸DNA免疫可诱导安全且具有保护性的免疫反应。
Acta Virol. 2018;62(2):137-146. doi: 10.4149/av_2018_203.
10
Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.JNJ-53718678 口服制剂在健康成年志愿者中抗呼吸道合胞病毒活性的研究:一项安慰剂对照研究。
J Infect Dis. 2018 Jul 24;218(5):748-756. doi: 10.1093/infdis/jiy227.